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Appropriate prescribing of PREGABALIN
Appropriate Prescribing 
 Undertake a risk/benefit assessment prior to prescribing
 Prescribe for a trial period to ascertain if effective
 Review on a regular basis for ongoing effectiveness.
In pain management, pregabalin is licensed for the treatment of neuropathic pain only.
Licensed Indications
Pregabalin is licensed for three therapeutic indications in adults:
 Treatment of peripheral and central neuropathic pain
 Treatment of generalised anxiety disorder
 Adjunctive therapy in patients with partial seizures with or without secondary 
generalisation.
The dose range is 150 mg - 600 mg per day (in either two or three divided doses).5
Vigilance is required when prescribing pregabalin due to the risk of dependence and the potential for illegal diversion and medicinal misuse.1
 The relaxant and sedative effects of pregabalin make it desirable for use outside of its three licensed indications.2 Patients misusing pregabalin describe improved 
sociability, euphoria, relaxation and a sense of calm.3 Pregabalin may be used to enhance the euphoric effects of other drugs such as opioids.2
 Drug-related death figures compiled by the Health Research Board have shown an increase in deaths where pregabalin was implicated, from 14 in 2013 to 45 in 2017.4
The Irish Medical Council advise all doctors prescribing pregabalin to follow best practice guidelines and to only prescribe when absolutely required (September 2019).
Counsel Patients Initiating Treatment on:
 The risk of harm with pregabalin including dependence6
 The risk of potentially fatal interactions between pregabalin and alcohol, and 
with other central nervous system (CNS) depressants, particularly opioids7
 The effect on ability to drive or operate machinery safely5
 The potential for withdrawal symptoms on discontinuation.5
Interactions with Central Nervous System Depressants
Pregabalin has adverse effects on the CNS.
These effects may be additive if pregabalin is taken with other CNS depressants
e.g. antidepressants, antipsychotics, anxiolytics, hypnotics and opioid analgesics.6
 Respiratory failure and coma have been reported in patients taking pregablin
and other CNS depressants.5
Renal Impairment
Dosage reduction is required in patients with impaired renal function.
Dosage reduction must be individualised based on creatinine clearance (see SmPC).5
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Withdrawal Symptoms 
 Can occur following discontinuation of short-term and long-term use.
 Symptoms include anxiety, convulsions, depression, diarrhoea, dizziness, flu 
syndrome, headache, hyperhidrosis, insomnia, nausea, nervousness and pain.5
Diversion
 Consider the ‘street value’ of pregabalin and monitor for signs of diversion e.g. 
requests for increased doses and quantities, early prescriptions or replacement of 
‘lost’ prescriptions.
Potential for Misuse, Abuse or Dependence
 Exercise caution if prescribing pregabalin for patients with a history of substance 
abuse. Monitor patients for symptoms of misuse, abuse or dependence.5
Side-effects
Tapering Dose
Public Health England (2014) suggest a gradual dose taper:
Reduce the dose weekly by a maximum of 50 – 100 mg.6
Specialist advice may be required to manage patients dependent on pregabalin.
 Refer to www.drugs.ie to access local services provided by the Addiction Services 
or Drugs and Alcohol Task Forces.
Very common side-effects are:
Dizziness Somnolence Headache 
Common side-effects include:5
Confusion Memory impairment Sedation Blurred vision 
Vertigo Erectile dysfunction Oedema Muscle cramp 
Fatigue Weight increase Vomiting Dry mouth
Amnesia Increased appetite Constipation Nasopharyngitis
Diplopia Flatulence Arthralgia Insomnia
